Pathology: la/mBC - HER2 positive - 2nd Line (L2); metastatic/advanced - breast cancer (mBC);
| la/mBC - HER2 positive - 2nd Line (L2) | metastatic/advanced - breast cancer (mBC) | ||
| DESTINY Breast03, 2022 | DESTINY-Breast04, 2022 | ||
| trastuzumab deruxtecan | 2 | T1 | T1 |
| trastuzumab emtansine | 0 | T0 | |
| chemotherapy | 0 | T0 |